

DAFTAR PUSTAKA

1. World Health Organization. Obesity and Overweight. SpringerReference. doi:10.1007/springerreference_223608
2. Neuschwander-Tetri BA. Fatty liver and metabolic syndrome. *Med Clin (Barc)*. 2007;141(6):252-253. doi:10.1016/j.medcli.2013.02.013
3. Meng K, Lee CH, Saremi F. Metabolic syndrome and ectopic fat deposition. What can CT and MR provide? *Acad Radiol*. 2010;17(10):1302-1312. doi:10.1016/j.acra.2010.03.019
4. Akbaş F, Usta Atmaca H, Değirmencioglu Ş. Evaluation of the Relationship Between Metabolic Syndrome, Visceral Adiposity Index and Lipid Accumulation Product in Patients with Obesity. *J Acad Res Med*. 2021;11(1):56-61. doi:10.4274/jarem.galenos.2021.21931
5. Jiang K, Luan H, Pu X, Wang M, Yin J, Gong R. Association Between Visceral Adiposity Index and Insulin Resistance: A Cross-Sectional Study Based on US Adults. *Front Endocrinol (Lausanne)*. 2022;13(July):1-10. doi:10.3389/fendo.2022.921067
6. Choi S, Diehl AM. Role of inflammation in nonalcoholic steatohepatitis. *Curr Opin Gastroenterol*. 2005;21(6):702-707. doi:10.1097/01.mog.0000182863.96421.47
7. Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. *J Hepatol*. 2019;71(4):793-801. doi:10.1016/j.jhep.2019.06.021
8. Manuscript A. Europe PMC Funders Group Current treatment paradigms and emerging therapies for NAFLD / NASH. 2021;(2):1-29.
9. Goffon C, Upendran Y, Zheng MH, George J. MAFLD: How is it different from NAFLD? *Clin Mol Hepatol*. 2023;29:S17-S31. doi:10.3350/cmh.2022.0367

10. Ismaiel A, Jaaouani A, Leucuta DC, Popa SL, Dumitrascu DL. The visceral adiposity index in non-alcoholic fatty liver disease and liver fibrosis—systematic review and meta-analysis. *Biomedicines*. 2021;9(12). doi:10.3390/biomedicines9121890
11. Vongsuvan R, George J, McLeod D, Van Der Poorten D. Visceral adiposity index is not a predictor of liver histology in patients with non-alcoholic fatty liver disease. *J Hepatol*. 2012;57(2):392-398. doi:10.1016/j.jhep.2012.03.013
12. Ebrahimi M, Seyedi SA, Nabipoorashrafi SA, et al. Lipid accumulation product (LAP) index for the diagnosis of nonalcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis. *Lipids Health Dis*. 2023;22(1):1-13. doi:10.1186/s12944-023-01802-6
13. Rotter I, Rył A, Szylińska A, Pawlukowska W, Lubkowska A, Laszczyńska M. Lipid Accumulation Product (LAP) as an Index of Metabolic and Hormonal Disorders in Aging Men. *Exp Clin Endocrinol Diabetes*. 2017;125(3):176-182. doi:10.1055/s-0042-116071
14. Kahn HS. The “lipid accumulation product” performs better than the body mass index for recognizing cardiovascular risk: A population-based comparison. *BMC Cardiovasc Disord*. 2005;5:1-10. doi:10.1186/1471-2261-5-26
15. Zhao S, Ren Z, Yu S, et al. Association between lipid accumulation product and target organ damage in elderly population: The northern shanghai study. *Clin Interv Aging*. 2021;16:1769-1776. doi:10.2147/CIA.S330313
16. Hashem A, Khalouf A, Acosta A. Management of Obesity and Nonalcoholic Fatty Liver Disease: A Literature Review. *Semin Liver Dis*. 2021;41(4):435-447. doi:10.1055/s-0041-1731704
17. Divella R, Mazzocca A, Daniele A, Sabbà C, Paradiso A. Obesity, nonalcoholic fatty liver disease and adipocytokines network in promotion of cancer. *Int J Biol Sci*.

- 2019;15(3):610-616. doi:10.7150/ijbs.29599
18. Caturano A, Acierno C, Nevola R, et al. Non-alcoholic fatty liver disease: From pathogenesis to clinical impact. *Processes*. 2021;9(1):1-18. doi:10.3390/pr9010135
 19. Branković M, Jovanović I, Dukić M, et al. Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis. *Int J Mol Sci*. 2022;23(9). doi:10.3390/ijms23095146
 20. Manal F. Abdelmalek AMD. *21st Edition Harrison's Principle's of Internal Medicine*. Volume 1. (Joseph Loscalzo, Dennis L. Kasper, Dan L. Longo, Anthony S. Fauci, Stephen L. Hauser LLJ, ed.). McGraw Hill LLC; 2022.
 21. Hazlehurst JM, Woods C, Marjot T, Cobbold JF, Tomlinson JW. Non-alcoholic fatty liver disease and diabetes. *Metabolism*. 2016;65(8):1096-1108. doi:10.1016/j.metabol.2016.01.001
 22. Rada P, González-Rodríguez Á, García-Monzón C, Valverde ÁM. Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver? *Cell Death Dis*. 2020;11(9). doi:10.1038/s41419-020-03003-w
 23. Marchesini G, Day CP, Dufour JF, et al. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol*. 2016;64(6):1388-1402. doi:10.1016/j.jhep.2015.11.004
 24. Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. *World J Gastroenterol*. 2018;24(30):3361-3373. doi:10.3748/wjg.v24.i30.3361
 25. Lazarus J V., Mark HE, Anstee QM, et al. Advancing the global public health agenda for NAFLD: a consensus statement. *Nat Rev Gastroenterol Hepatol*. 2022;19(1):60-78. doi:10.1038/s41575-021-00523-4
 26. Khang AR, Lee HW, Yi D, Kang YH, Son SM. The fatty liver index, a simple and useful

- predictor of metabolic syndrome: Analysis of the Korea national health and nutrition examination survey 2010–2011. *Diabetes, Metab Syndr Obes.* 2019;12:181-190. doi:10.2147/DMSO.S189544
27. Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments. *Nat Rev Gastroenterol Hepatol.* 2021;18(9):599-612. doi:10.1038/s41575-021-00448-y
 28. Hirano T. Pathophysiology of diabetic dyslipidemia. *J Atheroscler Thromb.* 2018;25(9):771-782. doi:10.5551/jat.RV17023
 29. Amato MC, Giordano C. Visceral adiposity index: An indicator of adipose tissue dysfunction. *Int J Endocrinol.* 2014;2014. doi:10.1155/2014/730827
 30. Qin Y, Qiao Y, Wang D, et al. Visceral adiposity index is positively associated with fasting plasma glucose: a cross-sectional study from National Health and Nutrition Examination Survey 2017–2020. *BMC Public Health.* 2023;23(1):1-11. doi:10.1186/s12889-023-15231-8
 31. Amato MC, Giordano C, Pitrone M, Galluzzo A. Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian Sicilian population. *Lipids Health Dis.* 2011;10(1):183. doi:10.1186/1476-511X-10-183
 32. Hulkoti V, Acharya S, Shukla S, et al. Visceral Adiposity Index in Type 2 Diabetes Mellitus (DM) and Its Correlation With Microvascular Complications. *Cureus.* 2022;14(Dm):1-26. doi:10.7759/cureus.31279
 33. Tsou MT, Chang YC, Hsu CP, et al. Visceral adiposity index outperforms conventional anthropometric assessments as predictor of diabetes mellitus in elderly Chinese: a population-based study. *Nutr Metab.* 2021;18(1). doi:10.1186/s12986-021-00608-6
 34. Lv C, Huo R. Association between visceral adiposity index, lipid accumulation product

- and type 2 diabetes mellitus in US adults with hypertension: a cross-sectional analysis of NHANES from 2005 to 2018. *BMC Endocr Disord.* 2024;24(1). doi:10.1186/s12902-024-01750-x
35. Cheng YL, Wang YJ, Lan KH, et al. Fatty Liver Index and Lipid Accumulation Product Can Predict Metabolic Syndrome in Subjects without Fatty Liver Disease. *Gastroenterol Res Pract.* 2017;2017. doi:10.1155/2017/9279836
 36. Finck BN. Targeting metabolism, insulin resistance, and diabetes to treat nonalcoholic steatohepatitis. *Diabetes.* 2018;67(12):2485-2493. doi:10.2337/dbi18-0024
 37. Hu H, Han Y, Cao C, He Y. The triglyceride glucose-body mass index: a non-invasive index that identifies non-alcoholic fatty liver disease in the general Japanese population. *J Transl Med.* 2022;20(1):1-18. doi:10.1186/s12967-022-03611-4
 38. Wakabayashi I, Daimon T. A strong association between lipid accumulation product and diabetes mellitus in Japanese women and men. *J Atheroscler Thromb.* 2014;21(3):282-288. doi:10.5551/jat.20628
 39. Ji B, Qu H, Wang H, Wei H, Deng H. Association between the Visceral Adiposity Index and Homeostatic Model Assessment of Insulin Resistance in Participants with Normal Waist Circumference. *Angiology.* 2017;68(8):716-721. doi:10.1177/0003319716682120
 40. Dai H, Wang W, Chen R, Chen Z, Lu Y, Yuan H. Lipid accumulation product is a powerful tool to predict non-alcoholic fatty liver disease in Chinese adults. *Nutr Metab.* 2017;14(1):1-9. doi:10.1186/s12986-017-0206-2
 41. Tang M, Wei XH, Cao H, et al. Association between Chinese visceral adiposity index and metabolic-associated fatty liver disease in Chinese adults with type 2 diabetes mellitus. *Front Endocrinol (Lausanne).* 2022;13(August):1-7. doi:10.3389/fendo.2022.935980

42. Schuppan D, Surabattula R, Wang XY. Determinants of fibrosis progression and regression in NASH. *J Hepatol.* 2018;68(2):238-250. doi:10.1016/j.jhep.2017.11.012
43. Kim D, Chung GE, Kwak MS, et al. Body Fat Distribution and Risk of Incident and Regressed Nonalcoholic Fatty Liver Disease. *Clin Gastroenterol Hepatol.* 2016;14(1):132-138.e4. doi:10.1016/j.cgh.2015.07.024
44. Schindhelm RK, Heine RJ, Diamant M. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients: Response to Targher et al. [2]. *Diabetes Care.* 2007;30(9). doi:10.2337/dc07-0982
45. Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. *Nat Rev Gastroenterol Hepatol.* 2017;14(1):32-42. doi:10.1038/nrgastro.2016.147
46. Colicchio P, Tarantino G, Del Genio F, et al. Non-alcoholic fatty liver disease in young adult severely obese non-diabetic patients in South Italy. *Ann Nutr Metab.* 2005;49(5):289-295. doi:10.1159/000087295
47. Zelber-Sagi S, Lotan R, Shlomain A, et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. *J Hepatol.* 2012;56(5):1145-1151. doi:10.1016/j.jhep.2011.12.011
48. Wong VWS, Wong GLH, Yeung DKW, et al. Incidence of non-Alcoholic fatty liver disease in Hong Kong: A population study with paired proton-magnetic resonance spectroscopy. *J Hepatol.* 2015;62(1):182-189. doi:10.1016/j.jhep.2014.08.041
49. Lomonaco R, Bril F, Portillo-Sanchez P, et al. Metabolic impact of nonalcoholic steatohepatitis in obese patients with type 2 diabetes. *Diabetes Care.* 2016;39(4):632-638. doi:10.2337/dc15-1876
50. Edens MA, Kuipers F, Stolk RP. Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers. *Obes Rev.* 2009;10(4):412-419. doi:10.1111/j.1467-789X.2009.00594.x

51. Kim D, Chung GE, Kwak MS, Kim YJ, Yoon JH. Effect of longitudinal changes of body fat on the incidence and regression of nonalcoholic fatty liver disease. *Dig Liver Dis.* 2018;50(4):389-395. doi:10.1016/j.dld.2017.12.014
52. Okamura T, Hashimoto Y, Hamaguchi M, Obora A, Kojima T, Fukui M. The visceral adiposity index is a predictor of incident nonalcoholic fatty liver disease: A population-based longitudinal study. *Clin Res Hepatol Gastroenterol.* 2020;44(3):375-383. doi:10.1016/j.clinre.2019.04.002
53. Xu C, Ma Z, Wang Y, et al. Visceral adiposity index as a predictor of NAFLD: A prospective study with 4-year follow-up. *Liver Int.* 2018;38(12):2294-2300. doi:10.1111/liv.13941
54. Yi X, Zhu S, Zhu L. Diagnostic accuracy of the visceral adiposity index in patients with metabolic-associated fatty liver disease: a meta-analysis. *Lipids Health Dis.* 2022;21(1):1-10. doi:10.1186/s12944-022-01636-8
55. Li H, Zhang Y, Luo H, Lin R. The lipid accumulation product is a powerful tool to diagnose metabolic dysfunction-associated fatty liver disease in the United States adults. *Front Endocrinol (Lausanne).* 2022;13(November):1-21. doi:10.3389/fendo.2022.977625
56. Balankhe K, Nayak RR, Modi RK, et al. Comparison of non-invasive scoring systems with ultrasound and liver elastography in predicting non-alcoholic fatty liver disease in healthy population. *Journal, Indian Acad Clin Med.* 2021;22(3-4):99-103.
57. Lin IT, Lee MY, Wang CW, Wu DW, Chen SC. Gender differences in the relationships among metabolic syndrome and various obesity-related indices with nonalcoholic fatty liver disease in a taiwanese population. *Int J Environ Res Public Health.* 2021;18(3):1-13. doi:10.3390/ijerph18030857